Evidence map›Paper›PMID 41430273›Full record

ArticleJournal of translational medicine2025

Dynamic screening initiation using 16 plasma protein biomarkers with polygenic risk and PLCOm2012: a precision prevention framework for lung cancer.

Runchen Wang, Zhiming Ye, Qixia Wang, Rong Xu, Yi Feng, Na Zhao, Yun Yan, Yulin Zhao, Xuanzhuang Lu, Xiangyuan Zheng and 8 more

Registry-linked trialAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06422637 (INFORM), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06422637 nanot yet recruitingnot on this map

INFORM: A Prospective Interventional Study on Early Screening for Lung Cancer Using Liquid Biopsy

TypeinterventionalSponsorThe First Affiliated Hospital of Guangzhou Medical UniversityRan2024 to 2027Enrolled5,944ConditionsLiquid Biopsy for Early Screening of Lung CancerArmsLiquid Biopsy Early Screening
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Runchen WangDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510120, China.
Zhiming YeDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510120, China.
Qixia WangDepartment of Respiratory and Critical Care Medicine, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Rong XuDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510120, China.
Yi FengDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510120, China.
Na ZhaoDepartment of Proteomics, Tianjin Key Laboratory of Clinical Multi-Omics, Tianjin, 300308, China.
Yun YanDepartment of Proteomics, Tianjin Key Laboratory of Clinical Multi-Omics, Tianjin, 300308, China.
Yulin ZhaoDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510120, China.
Xuanzhuang LuDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510120, China.
Xiangyuan ZhengDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510120, China.
Jianqi ZhengDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510120, China.
Hongsheng DengDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510120, China.
Ran ZhongDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510120, China.
Rui GaoDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510120, China.
Jie LiDepartment of Proteomics, Tianjin Key Laboratory of Clinical Multi-Omics, Tianjin, 300308, China.
Wenhua LiangDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510120, China. liangwh1987@163.com.
Jianxing HeDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510120, China. jianxinghe@gzhmu.edu.cn.
Hengrui LiangDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510120, China. hengrui_liang@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundlow-dose computed tomography (LDCT) screening strategies for lung cancer are primarily targeted at high-risk groups based on smoking history and age, leading to over-screening of low-risk individuals while delaying timely detection in high-risk groups. This study aimed to develop a precision screening framework integrating plasma proteomics, polygenic risk score (PRS), and the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial 2012 model (PLCOm2012) to enable dynamic and optimized screening strategies.

methodsA multicenter, multimodal study was conducted across two prospective cohorts. Plasma protein profiling identified 16 biomarkers, which were combined with PRS and PLCOm2012 to develop a prediction model. Protein score, PRS, and PLCOm2012 score were used to develop a combined risk score (CRS). Risk advancement period (RAP) analysis quantified personalized screening initiation ages based on 10-year cumulative risk thresholds.

resultsThe CRS demonstrated superior predictive accuracy, with 3-, 5-, and 10-year AUCs of 0.85 (95% CI: 0.80–0.93), 0.88 (95% CI: 0.83–0.92), and 0.85 (95% CI: 0.81–0.87), respectively. High-risk individuals yielded HR of 3.18 (95% CI: 2.34–4.31) with thresholds reached 11.71 (RAP: -11.71, 95% CI: –15.58 - −6.16) years earlier than those at medium-risk, while low-risk individuals could delay screening by 11.78 (RAP: 11.78, 95% CI: 6.95 - 15.08) years. Risk stratification revealed distinct differences in cumulative lung cancer incidence across groups. Personalized screening initiation ages suggested that high-risk individuals begin screening before age 40, while low-risk individuals could postpone screening until age 55 or later.

conclusionThis study developed a precision lung cancer screening framework by integrating plasma proteomics, genetic profiling, and clinical data. This approach enhanced early detection in high-risk individuals while safely delaying screening for low-risk groups.

trial registrationClinical trial number: NCT06422637.

Indexed as

Biomarkers, TumorBlood ProteinsEarly Detection of CancerLung NeoplasmsPrecision MedicineAgedFemaleGenetic Risk ScoreHumansMaleMiddle AgedRisk FactorsBiomarkers, TumorBlood ProteinsLung cancerPrecision oncologyProteomicsPRSRisk advancement period

Identifiers

PMID41430273
PMCPMC12903519

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.